NEW YORK, Feb. 03, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have
commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead
plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links
provided. There is no cost or obligation to you.
The Goldman Sachs Group, Inc. (NYSE: GS)
Class Period: February 28, 2014 - December 17, 2018
Lead Plaintiff Deadline: February 19, 2019
Join the action: https://www.zlk.com/pslra-1/the-goldman-sachs-group-inc-loss-form?wire=3
About the lawsuit: The Goldman Sachs Group, Inc. allegedly made materially false and/or misleading statements during the class
period and/or failed to disclose that: (1) Goldman Sachs participated in a fraud and money-laundering scheme in collusion with
1Malaysia Development Bhd., a Malaysian state-owned investment fund; (2) the foregoing conduct, when revealed, would foreseeably
subject Goldman Sachs to heightened regulatory investigations and enforcement; and (3) as a result, Goldman Sachs’s public
statements were materially false and misleading at all relevant times.
To learn more about the The Goldman Sachs Group, Inc. class action contact jlevi@levikorsinsky.com.
Dentsply Sirona, Inc. (NASDAQ: XRAY)
Class Period: (i) all persons who purchased the common stock of Dentsply Sirona, Inc. (NASDAQ: XRAY) between February 20,
2014 and August 7, 2018; (ii) all Dentsply International Inc. shareholders who held shares as of the record date of December 2,
2015 and were entitled to vote with respect to the Acquisition at the January 11, 2016 special meeting of Dentsply International
Inc. shareholders; and (iii) all persons who purchased or otherwise acquired the common stock of Dentsply International in exchange
for their shares of common stock of Sirona in connection with the Acquisition
Lead Plaintiff Deadline: February 19, 2019
Join the action: https://www.zlk.com/pslra-1/dentsply-sirona-inc-loss-form?wire=3
According to the complaint, during the Class Period, Defendants attributed the Company’s financial performance to the Company’s
“innovation,” “operational improvement efforts,” “new products,” and “continued investments in sales and marketing” and told
investors that these factors helped the Company succeed despite the “highly competitive” market for its products. In reality, the
Company’s financial results had been buoyed by an anticompetitive scheme among the Company’s three primary distributors that
suppressed competition in the dental supply market and artificially inflated the price of dental supplies sold by Dentsply.
Further, Defendants concealed that an exclusive distribution arrangement that Sirona had with one of its distributors, Patterson
Companies, Inc. (“Patterson”), required Patterson to regularly make large minimum purchases regardless of demand and, as a result,
by 2015, Patterson had been supplied with so much excess inventory that it could not be sold. This channel-stuffing rendered the
Company’s reported sales, financial results and guidance materially false and misleading. In addition, the Company
represented that it reported its financial statements, including its goodwill, in accordance with generally accepted accounting
principles, or GAAP. In fact, the Company’s reported goodwill was artificially inflated and not reported in accordance with GAAP
because it did not reflect the financial impact of the anticompetitive scheme.
To learn more about the Dentsply Sirona, Inc. class action contact jlevi@levikorsinsky.com.
Allergan plc (NYSE: AGN)
Class Period: May 9, 2017 - December 19, 2018
Lead Plaintiff Deadline: February 19, 2019
Join the action: https://www.zlk.com/pslra-1/allergan-plc-loss-form?wire=3
During the Class Period, and unbeknownst to investors, Allergan misled investors regarding various “pharma and device approvals”
and concealed the fact that the Company’s CE Mark for its textured breast implants and tissue expanders was expiring in
Europe.
On December 19, 2018, the Company announced that, following a compulsory recall request from Agence Nationale de Sécurité du
Médicament (“ANSM”), the French regulatory authority, the Company had suspended the sale of these products and that it was
withdrawing all remaining supplies from European markets. The suspension of sales stemmed directly from the expiration of the
company's CE Mark for these products, and the stock price fell drastically following the news.
To learn more about the Allergan plc class action contact jlevi@levikorsinsky.com.
DXC Technology Company (NYSE: DXC)
Class Period: February 8, 2018 - November 6, 2018
Lead Plaintiff Deadline: February 25, 2019
Join the action: https://www.zlk.com/pslra-1/dxc-technology-company-loss-form?wire=3
About the lawsuit: DXC Technology Company allegedly made materially false and/or misleading statements and/or failed to disclose
that: (a) the Company had changed or planned to change the operations of its sales teams, deploying generalized sales teams as
opposed to the specialized teams that were better capable of delivering specialized services to its clients; (b) the Company’s
workforce optimization strategy of sharply reducing staff while reducing costs was resulting in a shortage of sales personnel who
could execute on demand for services, thereby risking and ultimately losing sales and revenue opportunities; (c) in light of the
above, the Company’s revenue and financial performance guidance for the fiscal year 2019 and its reaffirmation of the guidance
during the Class Period was without a reasonable basis.
To learn more about the DXC Technology Company class action contact jlevi@levikorsinsky.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any
recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys
have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of
dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
